A Study of BMS-986340 as Monotherapy and in Combination With Nivolumab or Docetaxel in Participants With Advanced Solid Tumors
Bristol-Myers Squibb
Bristol-Myers Squibb
M.D. Anderson Cancer Center
BicycleTx Limited
Maastricht University Medical Center
Incyte Corporation
Incyte Corporation
Purple Biotech Ltd.
Astellas Pharma Inc
Compugen Ltd
Fate Therapeutics
Incyte Corporation
Five Prime Therapeutics, Inc.